SI3196194T1 - Pirimidinski derivati, uporabni kot selektivni inhibitorji JAK3 in/ali JAK1 - Google Patents
Pirimidinski derivati, uporabni kot selektivni inhibitorji JAK3 in/ali JAK1Info
- Publication number
- SI3196194T1 SI3196194T1 SI201530965T SI201530965T SI3196194T1 SI 3196194 T1 SI3196194 T1 SI 3196194T1 SI 201530965 T SI201530965 T SI 201530965T SI 201530965 T SI201530965 T SI 201530965T SI 3196194 T1 SI3196194 T1 SI 3196194T1
- Authority
- SI
- Slovenia
- Prior art keywords
- pyrimidine derivatives
- derivatives useful
- jak1 inhibitors
- selective jak3
- jak3
- Prior art date
Links
- 229940116839 Janus kinase 1 inhibitor Drugs 0.000 title 1
- 229940123241 Janus kinase 3 inhibitor Drugs 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410471468.9A CN105399685B (zh) | 2014-09-16 | 2014-09-16 | 作为选择性jak3和/或jak1激酶抑制剂的芳杂环化合物的制备方法及其应用 |
| PCT/CN2015/089499 WO2016041472A1 (zh) | 2014-09-16 | 2015-09-14 | 作为选择性jak3和/或jak1激酶抑制剂的芳杂环化合物的制备方法及其应用 |
| EP15842179.2A EP3196194B1 (en) | 2014-09-16 | 2015-09-14 | Pyrimidine derivatives useful as selective jak3 and/or jak1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3196194T1 true SI3196194T1 (sl) | 2019-12-31 |
Family
ID=55465491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201530965T SI3196194T1 (sl) | 2014-09-16 | 2015-09-14 | Pirimidinski derivati, uporabni kot selektivni inhibitorji JAK3 in/ali JAK1 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10011571B2 (sl) |
| EP (1) | EP3196194B1 (sl) |
| JP (1) | JP6516305B2 (sl) |
| KR (1) | KR101971887B1 (sl) |
| CN (1) | CN105399685B (sl) |
| AU (1) | AU2015317937B2 (sl) |
| BR (1) | BR112017005113B1 (sl) |
| CA (1) | CA2982881C (sl) |
| CY (1) | CY1122423T1 (sl) |
| DK (1) | DK3196194T3 (sl) |
| ES (1) | ES2754403T3 (sl) |
| HK (1) | HK1220975A1 (sl) |
| HR (1) | HRP20191734T1 (sl) |
| HU (1) | HUE045899T2 (sl) |
| LT (1) | LT3196194T (sl) |
| PL (1) | PL3196194T3 (sl) |
| PT (1) | PT3196194T (sl) |
| RS (1) | RS59467B1 (sl) |
| RU (1) | RU2671195C2 (sl) |
| SI (1) | SI3196194T1 (sl) |
| TW (1) | TWI570109B (sl) |
| WO (1) | WO2016041472A1 (sl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020326627A1 (en) * | 2019-08-02 | 2022-03-17 | Amgen Inc. | KIF18A inhibitors |
| JP2023500352A (ja) * | 2019-11-08 | 2023-01-05 | 深▲セン▼微芯生物科技股▲フン▼有限公司 | 移植片対宿主病を予防又は治療するための化合物 |
| CN112933049B (zh) * | 2019-11-26 | 2024-02-06 | 深圳微芯生物科技股份有限公司 | 含无定型态芳杂环化合物的组合物、其制备方法及用途 |
| CN111297866B (zh) * | 2020-03-09 | 2021-04-02 | 深圳微芯生物科技股份有限公司 | 一种包含jak3/jak1/tbk1抑制剂和甲氨蝶呤的药物组合物及其用途 |
| CN117136059A (zh) * | 2021-04-22 | 2023-11-28 | 深圳微芯生物科技股份有限公司 | 包含jak3/jak1/tbk1选择性抑制剂的药物组合物及其医药用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004048343A1 (en) * | 2002-11-28 | 2004-06-10 | Schering Aktiengesellschaft | Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
| CN101421250A (zh) * | 2006-01-30 | 2009-04-29 | 埃克塞里艾克西斯公司 | 作为jak-2调节剂的4-芳基-2-氨基-嘧啶或4-芳基-2-氨基烷基-嘧啶及包含它们的药物组合物 |
| ATE497496T1 (de) * | 2006-10-19 | 2011-02-15 | Rigel Pharmaceuticals Inc | 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen |
| JP5539734B2 (ja) * | 2007-01-31 | 2014-07-02 | ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド | チオピリミジンベースの化合物およびその使用 |
| US8338439B2 (en) * | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| JP2011526299A (ja) * | 2008-06-27 | 2011-10-06 | アビラ セラピューティクス， インコーポレイテッド | ヘテロアリール化合物およびそれらの使用 |
| DE102009001438A1 (de) | 2009-03-10 | 2010-09-16 | Bayer Schering Pharma Aktiengesellschaft | Carbonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| CN101906076B (zh) * | 2009-06-04 | 2013-03-13 | 深圳微芯生物科技有限责任公司 | 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用 |
| CN103073508B (zh) * | 2011-10-25 | 2016-06-01 | 北京大学深圳研究生院 | 激酶抑制剂及治疗相关疾病的方法 |
| CN104109127B (zh) * | 2013-04-19 | 2019-11-05 | 北京大学深圳研究生院 | 激酶抑制剂及治疗相关疾病的方法 |
-
2014
- 2014-09-16 CN CN201410471468.9A patent/CN105399685B/zh active Active
-
2015
- 2015-09-14 CA CA2982881A patent/CA2982881C/en active Active
- 2015-09-14 BR BR112017005113-3A patent/BR112017005113B1/pt active IP Right Grant
- 2015-09-14 DK DK15842179T patent/DK3196194T3/da active
- 2015-09-14 US US15/510,758 patent/US10011571B2/en active Active
- 2015-09-14 HU HUE15842179A patent/HUE045899T2/hu unknown
- 2015-09-14 PL PL15842179T patent/PL3196194T3/pl unknown
- 2015-09-14 RS RSP20191336 patent/RS59467B1/sr unknown
- 2015-09-14 JP JP2017533675A patent/JP6516305B2/ja active Active
- 2015-09-14 KR KR1020177009942A patent/KR101971887B1/ko active IP Right Grant
- 2015-09-14 ES ES15842179T patent/ES2754403T3/es active Active
- 2015-09-14 EP EP15842179.2A patent/EP3196194B1/en active Active
- 2015-09-14 RU RU2017112299A patent/RU2671195C2/ru active
- 2015-09-14 SI SI201530965T patent/SI3196194T1/sl unknown
- 2015-09-14 AU AU2015317937A patent/AU2015317937B2/en active Active
- 2015-09-14 WO PCT/CN2015/089499 patent/WO2016041472A1/zh active Application Filing
- 2015-09-14 PT PT158421792T patent/PT3196194T/pt unknown
- 2015-09-14 LT LTEP15842179.2T patent/LT3196194T/lt unknown
- 2015-09-15 TW TW104130419A patent/TWI570109B/zh active
-
2016
- 2016-08-01 HK HK16109126.0A patent/HK1220975A1/zh unknown
-
2019
- 2019-09-25 HR HRP20191734 patent/HRP20191734T1/hr unknown
- 2019-10-25 CY CY20191101116T patent/CY1122423T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3196194A1 (en) | 2017-07-26 |
| CN105399685B (zh) | 2018-05-22 |
| CA2982881C (en) | 2020-02-25 |
| DK3196194T3 (da) | 2019-10-28 |
| ES2754403T3 (es) | 2020-04-17 |
| PT3196194T (pt) | 2019-11-18 |
| JP6516305B2 (ja) | 2019-05-22 |
| HK1220975A1 (zh) | 2017-05-19 |
| LT3196194T (lt) | 2019-10-10 |
| RU2017112299A (ru) | 2018-10-17 |
| EP3196194A4 (en) | 2018-05-30 |
| TWI570109B (zh) | 2017-02-11 |
| AU2015317937A1 (en) | 2017-04-27 |
| CY1122423T1 (el) | 2021-01-27 |
| CA2982881A1 (en) | 2016-03-24 |
| RU2671195C2 (ru) | 2018-10-30 |
| US20170253566A1 (en) | 2017-09-07 |
| KR101971887B1 (ko) | 2019-04-25 |
| TW201612165A (en) | 2016-04-01 |
| PL3196194T3 (pl) | 2020-01-31 |
| BR112017005113A2 (pt) | 2018-01-23 |
| HUE045899T2 (hu) | 2020-01-28 |
| US10011571B2 (en) | 2018-07-03 |
| CN105399685A (zh) | 2016-03-16 |
| KR20170048593A (ko) | 2017-05-08 |
| HRP20191734T1 (hr) | 2019-12-13 |
| RU2017112299A3 (sl) | 2018-10-17 |
| WO2016041472A1 (zh) | 2016-03-24 |
| EP3196194B1 (en) | 2019-08-07 |
| RS59467B1 (sr) | 2019-11-29 |
| BR112017005113B1 (pt) | 2023-02-14 |
| JP2017527625A (ja) | 2017-09-21 |
| AU2015317937B2 (en) | 2018-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL247949A0 (en) | New histories of pyrazolopyrimidines and their use as malt1 inhibitors | |
| HK1252752A1 (zh) | 新型吡唑並嘧啶衍生物 | |
| IL291265A (en) | Selective jak1 inhibitors and their uses | |
| IL254224A0 (en) | 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors | |
| IL259150B (en) | Pyrimidine derivative and use thereof | |
| ZA201906875B (en) | Jak1 selective inhibitors | |
| ZA201708568B (en) | Pyrimidine derivatives as btk inhibitors and uses thereof | |
| IL259796A (en) | Aza-benzimidazole inhibitors of pad4 | |
| EP3102571A4 (en) | SUBSTITUTED PYRIMIDINES USEFUL AS EGFR-T790M KINASE INHIBITORS | |
| RS59467B1 (sr) | Derivati pirimidina korisni kao selektivni jak3 i/ili jak1 inhibitori | |
| HK1250028A1 (zh) | 2-苯基-6-咪唑基-吡啶-4-甲酰胺衍生物及其作為eaat3抑制劑的用途 | |
| HK1252767A1 (zh) | 作為eaat3抑制劑的吡唑-吡啶衍生物 | |
| IL258690A (en) | Pyridone derivatives and their use as kinase inhibitors | |
| EP3551632C0 (en) | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | |
| GB201509381D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201505460D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201409661D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201405532D0 (en) | Novel compounds and their use as Kinase inhibitors |